Phibro Animal Health (NASDAQ:PAHC) Shares Down 4.3% – Time to Sell?

Phibro Animal Health Corporation (NASDAQ:PAHC) shares were down 4.3% during trading on Thursday . The stock traded as low as $38.26 and last traded at $38.2050. 37,577 shares were traded during trading, a decline of 87% from the average session volume of 296,314 shares. The stock had previously closed at $39.92.

Analysts Set New Price Targets

Several research analysts have weighed in on PAHC shares. Wall Street Zen downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Citigroup reduced their price objective on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Finally, Weiss Ratings lowered shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Phibro Animal Health has an average rating of “Hold” and a consensus price target of $47.67.

Phibro Animal Health Price Performance

The company has a market cap of $1.56 billion, a PE ratio of 15.79, a price-to-earnings-growth ratio of 1.11 and a beta of 0.46. The company has a quick ratio of 1.27, a current ratio of 2.96 and a debt-to-equity ratio of 1.84. The business’s 50 day moving average price is $34.62 and its 200-day moving average price is $41.95.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, August 26th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.14. The firm had revenue of $396.75 million during the quarter, compared to analyst estimates of $381.18 million. Phibro Animal Health had a return on equity of 37.86% and a net margin of 6.57%.Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. As a group, analysts forecast that Phibro Animal Health Corporation will post 3.51 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Wednesday, September 2nd will be given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 2nd. Phibro Animal Health’s dividend payout ratio is currently 19.67%.

Hedge Funds Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently modified their holdings of PAHC. 1620 Investment Advisors Inc. boosted its stake in Phibro Animal Health by 77.4% during the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after buying an additional 386 shares during the period. KBC Group NV purchased a new position in Phibro Animal Health during the 1st quarter worth approximately $29,000. Rothschild Investment LLC raised its position in Phibro Animal Health by 2,500.0% during the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after buying an additional 1,000 shares during the period. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Phibro Animal Health during the third quarter worth approximately $61,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.